<!--
title: Toxic Epidermal Necrolysis Post COVID-19 Vaccination - First Reported Case
description: doi: 10.7759/cureus.17215
published: true
date: 2022-01-13T10:44:25.647Z
tags: #vaccine, #risk, #side, #effects, #johnson, #study, #syndrome, #stevens, #case, #report, #toxic, #epidermal, #necrolysis, #sjs, #ten
editor: ckeditor
dateCreated: 2022-01-13T10:44:23.292Z
-->

<p><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442571/#">Cureus.</a> 2021 Aug; 13(8): e17215.</p>
<p>Published online 2021 Aug 16. doi:&nbsp;<a href="https://dx.doi.org/10.7759%2Fcureus.17215">10.7759/cureus.17215</a></p>
<p style="text-align:right;">PMCID: PMC8442571</p>
<p style="text-align:right;">PMID: <a href="https://www.ncbi.nlm.nih.gov/pubmed/34540442">34540442</a></p>
<p>&nbsp;</p>
<h1>Toxic Epidermal Necrolysis Post COVID-19 Vaccination - First Reported Case</h1>
<p>Monitoring Editor: Alexander Muacevic and John R Adler</p>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Bakir%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=34540442">Mohamad Bakir</a>,<sup>1</sup> <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Almeshal%20H%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=34540442">Hanan Almeshal</a>,<sup>2</sup> <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Alturki%20R%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=34540442">Rifah Alturki</a>,<sup>2</sup> <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Obaid%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=34540442">Sulaiman Obaid</a>,<sup>2</sup> and <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Almazroo%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=34540442">Areej Almazroo</a><sup>2</sup></p>
<p style="text-align:right;">&nbsp;</p>
<h2>Abstract</h2>
<p>Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a spectrum of acute, delayed-type hypersensitivity reactions that affect the skin and the mucous membranes. Medications are the culprit cause of these disorders in addition to infections and in very rare instances vaccinations. We report a case of TEN in a 49-year-old woman with no previous medical history. The disorder developed one week after receiving the first dose of COVID-19 vaccine with no other identifiable causes. The patient received two doses of tumor necrosis factor-alpha inhibitor (etanercept) and she stopped developing new lesions after two days of the initial dose; complete healing was observed after 22 days&nbsp;and no side effects were observed in our patient. This case demonstrates an extremely rare complication to the COVID-19 vaccine. The benefits of receiving the COVID-19 outweigh the potential risk.&nbsp;</p>
<p><strong>Keywords: </strong>toxic epidermal necrolysis, vaccination, covid-19, stevens-johnson-syndrome, etanercept, case report.</p>
<p>&nbsp;</p>
<p>Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442571/</p>
